Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$9.07 -3.1%	$5.78	$3.39 ▼ $16.00	$119.27M	0.8	108,214 shs	105,289 shs
ELEV Elevation Oncology	$0.37	$0.37	$0.22 ▼ $3.09	$21.62M	1.48	1.18 million shs	N/A
EXOZ eXoZymes	$9.99 -0.4%	$10.67	$8.50 ▼ $23.99	$83.60M	N/A	14,787 shs	2,415 shs
VXRT Vaxart	$0.38 +1.2%	$0.44	$0.26 ▼ $1.07	$88.02M	1.12	3.10 million shs	729,995 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+3.88%	+14.15%	+95.82%	+160.00%	-5.45%
ELEV Elevation Oncology	0.00%	0.00%	-3.16%	+6.85%	-49.26%
EXOZ eXoZymes	+1.72%	-0.59%	+2.24%	-29.47%	+1,002,999,900.00%
VXRT Vaxart	+4.79%	+5.45%	-13.58%	-3.25%	-33.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTX Avalo Therapeutics	2.4678 of 5 stars	3.5	3.0	0.0	0.0	1.6	1.7	0.6
ELEV Elevation Oncology	2.3045 of 5 stars	3.0	5.0	0.0	0.0	0.6	1.7	0.6
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	2.7452 of 5 stars	3.5	5.0	0.0	0.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	3.00	Buy	$30.00	230.76% Upside
ELEV Elevation Oncology	2.00	Hold	$2.62	616.89% Upside
EXOZ eXoZymes	0.00	N/A	N/A	N/A
VXRT Vaxart	3.00	Buy	$3.00	680.23% Upside

Current Analyst Ratings Breakdown

Latest ELEV, AVTX, VXRT, and EXOZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$440K	271.07	N/A	N/A	$7.95 per share	1.14
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	$1.25 per share	N/A
VXRT Vaxart	$47.40M	1.86	N/A	N/A	$0.26 per share	1.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	-48.48%	-35.94%	N/A
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	N/A
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	-$66.95M	-$0.27	N/A	N/A	N/A	-122.63%	-91.89%	-38.40%	8/13/2025 (Estimated)

Latest ELEV, AVTX, VXRT, and EXOZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	VXRT Vaxart	-$0.08	N/A	N/A	N/A	$2.03 million	N/A
8/12/2025	Q2 2025	EXOZ eXoZymes	N/A	-$0.28	N/A	-$0.28	N/A	N/A
8/7/2025	Q2 2025	AVTX Avalo Therapeutics	-$1.43	-$1.92	-$0.49	-$1.92	N/A	N/A
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
5/13/2025	Q1 2025	VXRT Vaxart	-$0.07	-$0.07	N/A	-$0.07	$2.85 million	$20.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	12.44	12.44
ELEV Elevation Oncology	0.67	19.40	19.40
EXOZ eXoZymes	N/A	6.52	6.52
VXRT Vaxart	N/A	0.64	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
ELEV Elevation Oncology	83.70%
EXOZ eXoZymes	N/A
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	0.25%
ELEV Elevation Oncology	8.10%
EXOZ eXoZymes	72.41%
VXRT Vaxart	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	13.15 million	13.12 million	Not Optionable
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable
EXOZ eXoZymes	29	8.37 million	2.31 million	N/A
VXRT Vaxart	120	228.92 million	222.37 million	Optionable

ELEV, AVTX, VXRT, and EXOZ Headlines

Recent News About These Companies

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

1 hour ago | reuters.com

Vaxart (NASDAQ:VXRT) Stock Price Passes Below 200-Day Moving Average - Here's Why

August 7, 2025 | marketbeat.com

Vaxart (VXRT) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Vaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split Proposal

July 31, 2025 | quiverquant.comQ

Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average - Here's Why

July 29, 2025 | marketbeat.com

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

July 24, 2025 | globenewswire.com

Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - What's Next?

July 19, 2025 | marketbeat.com

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

July 8, 2025 | financialpost.comF

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

June 13, 2025 | globenewswire.com

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

June 11, 2025 | globenewswire.com

Vaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025

June 10, 2025 | quiverquant.comQ

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

June 10, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

June 2, 2025 | globenewswire.com

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025 | globenewswire.com

Vaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025

May 29, 2025 | quiverquant.comQ

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025 | globenewswire.com

Vaxart Discusses Reverse Stock Split and Capital Raise

May 28, 2025 | tipranks.com

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025 | globenewswire.com

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Vaxart, Inc. Grants Equity Awards to New CFO Jeroen Grasman

May 20, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ELEV, AVTX, VXRT, and EXOZ Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$9.07 -0.29 (-3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$8.93 -0.14 (-1.59%)

As of 05:00 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Elevation Oncology NASDAQ:ELEV

$0.36 0.00 (0.00%)

As of 07/23/2025

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

eXoZymes NASDAQ:EXOZ

$9.99 -0.04 (-0.40%)

As of 02:13 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Vaxart NASDAQ:VXRT

$0.38 +0.00 (+1.18%)

As of 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time